Learn More
BACKGROUND AND AIM Hepatitis B surface antigen (HBsAg) clearance is the closest cure outcome in hepatitis B. The goal of this study was to investigate clinical features in chronic hepatitis B patients achieving seroconversion of HBsAg after treatment with α-interferon (IFN-α) and a nucleos(t)ide analog. METHODS This retrospective study enrolled 38 chronic(More)
BACKGROUND To control HIV globally, a comprehensive understanding of host immunity to HIV in different human populations is needed. Relatively, little is known on the quantity and quality of HIV-specific T-cell responses in Chinese patients. METHODS We quantified HIV Gag-specific CD8+ and CD4+ T cells that are capable of producing interferon (IFN)-gamma(More)
—Time efficiency in key establishment and update is one of the major problems contributory key managements strive to improve. In this paper, we present a contributory group key management based on Weighted-Join-Exit-Tree and named as WJT to get better time efficiency in key update. Built upon tree-based group key management, WJT has three improvements, the(More)
BACKGROUND Many factors are associated with post-treatment relapse in CHB patients, and there are no effective factors to predict relapse. In this study, we investigate the influence factors associated with post-treatment relapse and their predictive value in HBeAg positive CHB (eP-CHB). METHODS The factors associated with post-treatment relapse were(More)
BACKGROUND HBsAg clearance represents a clinical cure although the clearance rate is extremely low. The aim of this study was to evaluate the feasibility and safety profiles of pegylated-interferon α-2a (PEG-IFNα-2a) as a therapeutic option for inactive HBsAg carriers (IHCs). METHODS 144 IHCs were enrolled and divided into a therapeutic group (102(More)
  • 1